Entropy Neurodynamics

Entropy Neurodynamics Financing Cash Flow

The Net Financing Cash Flow of Entropy Neurodynamics (ENP.AX) as of Nov 22, 2026 is 5.97 M AUD. In the previous year, Net Financing Cash Flow was 5.60 M AUD — a change of 6.71% (higher).

Financing Cash Flow

5.97 MAUD

YoY

6.71%

Last updated:

Net Financing Cash Flow of Entropy Neurodynamics is 2026 5.97 M AUD. Net Financing Cash Flow of Entropy Neurodynamics was 2025 5.60 M AUD. It decreases by 6.71% higher compared to the previous year.

The Entropy Neurodynamics Financing Cash Flow history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Financing Cash Flow
Date
Financing Cash Flow
Jan 1, 2019
7.41 M AUD
Jan 1, 2020
4.99 M AUD
Jan 1, 2021
20.61 M AUD
Jan 1, 2022
1.95 M AUD
Jan 1, 2023
2.39 M AUD
Jan 1, 2024
9.27 M AUD
Jan 1, 2025
5.60 M AUD
Jan 1, 2026
5.97 M AUD
The Entropy Neurodynamics Financing Cash Flow history
YEARFinancing Cash FlowYoY
5.97 MAUD+6.71%
5.60 MAUD-39.63%
9.27 MAUD+288.69%
2.39 MAUD+22.35%
1.95 MAUD-90.54%
20.61 MAUD+312.81%
4.99 MAUD-32.63%
7.41 MAUD+4,328.24%
167,329.00AUD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Entropy Neurodynamics Stock analysis

What does Entropy Neurodynamics do? Entropy Neurodynamics Ltd develops and commercializes exosomes as therapeutic agents. The company holds intellectual property related to exosome technology and offers LEAP manufacturing, LOAD API loading, and EVPS tropism technologies. Pharmaceutical and biotechnology companies purchase these proprietary technologies to enhance their own exosome-based products. The firm invests in biopharmaceutical drug development and leverages its portfolio of know-how to support partners in exosome medicine development. Exopharm Ltd. is the company's brand name, and it operates through its exosome technology portfolio. The firm's technologies solve key challenges in exosome medicine success, including manufacturing efficiency and targeted delivery. Biopharmaceutical companies are the primary buyers of these technologies, seeking to integrate exosome delivery systems into their therapeutic pipelines. The company's business model centers on licensing its exosome-related IP and know-how to pharmaceutical and biotech firms. By providing LEAP, LOAD API, and EVPS technologies, Entropy Neurodynamics enables partners to overcome technical barriers in exosome-based drug development. This approach generates revenue through technology licensing agreements with industry partners. Entropy Neurodynamics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Entropy Neurodynamics stock

Net Financing Cash Flow of Entropy Neurodynamics is 5.97 M AUD in 2026.

Net Financing Cash Flow of Entropy Neurodynamics changed from 5.60 M AUD to 5.97 M AUD, representing a 6.71% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Financing Cash Flow Entropy Neurodynamics since 2006 – with annual values, charts, and detailed analysis.

Financing cash flow measures cash flows from debt issuance/repayment, equity transactions, and dividend payments.

Net Financing Cash Flow's AUD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Financing Cash Flow's Entropy Neurodynamics historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Entropy Neurodynamics

All Key Metrics — Entropy Neurodynamics